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Abstract
In many types of cancers, a side population (SP) has been identified based on high efflux capacity, thereby enriching for
chemoresistant cells as well as for candidate cancer stem cells (CSC). Here, we explored whether human pancreatic ductal
adenocarcinoma (PDAC) contains a SP, and whether its gene expression profile is associated with chemoresistance, CSC and
prognosis. After dispersion into single cells and incubation with Hoechst dye, we analyzed human PDAC resections
specimens using flow cytometry (FACS). We identified a SP and main population (MP) in all human PDAC resection
specimens (n = 52) analyzed, but detected immune (CD45+) and endothelial (CD31+) cells in this fraction together with
tumor cells. The SP and MP cells, or more purified fractions depleted from CD31+/CD45+ cells (pSP and pMP), were sorted by
FACS and subjected to whole-genome expression analysis. This revealed upregulation of genes associated with therapy
resistance and of markers identified before in putative pancreatic CSC. pSP gene signatures of 32 or 10 up- or
downregulated genes were developed and tested for discriminatory competence between pSP and pMP in different sets of
PDAC samples. The prognostic value of the pSP genes was validated in a large independent series of PDAC patients (n = 78)
using nCounter analysis of expression (in tumor versus surrounding pancreatic tissue) and Cox regression for disease-free
and overall survival. Of these genes, expression levels of ABCB1 and CXCR4 were correlated with worse patient survival. Thus,
our study for the first time demonstrates that human PDAC contains a SP. This tumor subpopulation may represent a
valuable therapeutic target given its chemoresistance- and CSC-associated gene expression characteristics with potential
prognostic value.
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Introduction
Despite large efforts to improve its prognosis, pancreatic cancer
(pancreatic ductal adenocarcinoma or PDAC) remains a major
cause of cancer-related mortality [1]. Delayed detection and
therapy resistance are critical determinants of PDAC treatment
failure. A better understanding of the mechanisms underlying
therapy resistance is therefore essential. In several types of cancer,
a side population (SP) has been identified as a subpopulation that
enriches for cells that are chemo- and radioresistant due to the
presence of multidrug transporters and the capacity to repair DNA
damage and withstand apoptosis [2]. Based on their efflux
capacity, SP cells are identified in flow-cytometric (FACS) analysis
as a side branch of ‘Hoechst-low’ cells after incubation with the
Hoechst33342 dye [3].
Therapy resistance is also considered a particular characteristic
of so-called ‘cancer stem cells’ (CSC) [4]. CSC are thought to
survive conventional therapies and therefore responsible for tumor
relapse. Candidate pancreatic CSC populations have recently
been identified based on cell membrane markers. CD24+/CD44+/
epithelial cell adhesion molecule (EPCAM)+ cells and CD133+
cells were shown to display CSC properties [5,6]. However, only
partial overlap was found between these different pancreatic CSC
populations, indicating the need for alternative identification
strategies. In various cancer types, the SP has been shown to be
enriched for CSC(-like) phenotype and activity [7]. Regarding
pancreatic cancer, a SP was previously found in cultured cell lines
[8–11], and recently, our group identified a SP in xenograft
tumors grown from human PDAC samples in immunodeficient
mice [12]. These SPs were demonstrated to possess chemoresistant
capacity. However, it has not been shown whether PDAC directly
from the patient, without intervening culture or expansion in the
murine host environment, also contains a SP. In the present study,
we report that PDAC isolated from patients harbors a SP and that
this SP expresses genes associated with pancreatic CSC and
chemoresistance, as well as with patient prognosis.
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Materials and Methods
PDAC Samples and SP Analysis
Between 2008 and 2010, PDAC surgical resection specimens
were obtained from 52 patients at the University Hospital Leuven
(UZ Leuven, Belgium) after written informed consent. The study
was approved by the UZ/KU Leuven Ethical Committee prior to
patient recruitment, and received the study number ML3452. The
study was registered at clinicaltrials.gov under the number
NCT00936104. After resection, tumor blocks were minced into
small pieces and incubated with collagenase type IV (1 mg/ml in
Medium 199; Invitrogen, Grand Island, NY) for 2–3 hr while
mechanically dispersed at regular 20-min time points. The final
cell suspension was filtered through a 40 mm nylon mesh (BD
Biosciences, Erembodegem, Belgium), and cell number and
viability determined. The viability of the cells obtained after
dispersion of the PDAC tissues was routinely ,50% and the yield
of 400 mm3 freshly obtained PDAC samples was approximately
36106 living cells.
SP analysis was done as described before 3. Cells were incubated
with Hoechst33342 (Sigma-Aldrich, Bornem, Belgium) during
90 min at a final concentration of 5 mg/ml, and analysed by
FACS (FACSVantage SE, equipped with FACS DIVA software,
version 6.0; BD Biosciences). The lasers used were: near-UV
(375 nm, 10 mW output), blue (488 nm, 13 mW) and yellow-
green (561 nm, 30 mW). The filters used were: 450/40 for
Hoechst blue; 630/22 and 610 LP for Hoechst red; 530/30 and
520 LP for FITC; and 582/15 for PE. Propidium iodide (2 mg/ml;
Sigma-Aldrich) was added to mark non-viable cells, excluding the
debris in the Hoechst-blue and Hoechst-red channel. Dual-
wavelength FACS analysis identified a side branch of ‘Hoechst-
low’ cells as the SP, further verified by co-adding verapamil
(100 mM; Sigma-Aldrich) which results in reduction of the SP size
by blocking the dye efflux through multidrug transporter(s). The
main population (MP) was gated as the bulk of ‘Hoechst-bright’
cells. For further characterization, PDAC cells were immuno-
stained for the endothelial marker CD31 and the hematopoietic/
immune marker CD45. After incubation with Hoechst, the cells
were dissolved in staining buffer (PBS +2% FBS), and fluorescein
(FITC)-labeled anti-human CD31 and phycoerythrin (PE)-labeled
anti-human CD45 antibodies were added using dilutions recom-
mended by the manufacturer (BD Biosciences). Both isotype (BD
Biosciences) and positive controls were performed. Additional
stainings were not done as these could impede analysis of the
FACS outcome.
Whole-genome Expression Analysis by Microarray
25000 SP and 25000 MP cells (total or depleted from CD45+/
CD31+ cells) were sorted by FACS into cold lysis solution of the
RNeasy Micro Kit (Qiagen, Venlo, The Netherlands). Total RNA
was extracted according to the instructions of the manufacturer.
RNA concentration and purity were determined spectrophoto-
metrically using the Nanodrop ND-1000 system (Nanodrop
Technologies, Wilmington, DE) and RNA integrity was assessed
using a Bioanalyser 2100 (Agilent Technologies, Santa Clara, CA).
Only samples with RNA Integrity Number (RIN) $7.5 were used
for further microarray analysis at the VIB Nucleomics Core (www.
nucleomics.be). RNA was amplified with the NuGEN Pico WTA
kit (Nugen Technologies, Santa Carlos, CA) and subsequently
biotinylated. The final aRNA mixture was purified and fragment-
ed, and then hybridized on Affymetrix HG U133 Plus 2.0 arrays
(Affymetrix, Santa Clara, CA), followed by staining and washing in
a GeneChip fluidics station 450 (Affymetrix) according to the
manufacturer’s procedures. To measure the raw probe signal
intensities, chips were scanned using a GeneChip scanner 3000
(Affymetrix) and analysed with the affy_1.26.0 package (Biocon-
ductor, Seattle, WA).
Statistical and Functional Analysis of Microarray Data
The raw microarray data were normalized within arrays and
between arrays following the Robust Multichip Average (RMA)
procedure [13]. The MAS 5.0 algorithm (Microarray suite user
guide, version 5; Affymetrix 2001) was used to assess detection
above background. From the 54616 probe sets, 10255 were below
background and omitted from further analysis. Principal Compo-
nent Analysis (PCA) was done with the pcurve package from
Bioconductor and used to compute the main sources of variation
between the samples. For comparative analysis between SP and
MP, data were paired per patient. The limma package from
Bioconductor was used to assess the contrast between SP and MP
[14]. Statistical significance of this contrast was tested with a
moderated t-test (implemented in limma). Significantly up- or
downregulated genes were defined as genes with $2-fold change
(log2 SP/MP$1 or#21), in combination with p,0.001. Classical
schemes to adjust for multiple testing can result in low statistical
power for microarray studies. The stringent cut-off of p,0.001
was used as an alternative, pragmatic approach to balance the
number of false positives and false negatives [15]. Gene expression
data are available from the Gene Expression Omnibus (GEO,
http://www.ncbi.nlm.nih.gov/projects/geo/) through series ac-
cession number GSE42404. Functional pathway analysis on all
significantly differentially expressed probe sets was done with the
Ingenuity Pathway Analysis (IPA) program (Ingenuity Systems,
www.ingenuity.com; Redwood City, CA), built on the Ingenuity
Knowledge Base, a manually curated literature database. All
probe sets with a corrected p-value ,0.001 and a fold change of
.2 or,22 were used as input. In case multiple probes referred to
the same gene, the average log2-ratio of the set of entry values for
this gene was taken for further analysis. Generated networks were
ordered by a score meaning significance, estimated as the ratio of
the number of input probes that mapped to the pathway divided
by the total number of pathway probes. Significance of biological
functions and canonical pathways were tested by the Fisher’s exact
test p-value after application of Benjamini-Hochberg method of
multiple testing correction. Pathways were considered significant
when p,0.05. Additional identification of biological functions
(Gene Ontology, GO) and KEGG (Kyoto Encyclopedia of Genes
and Genomes) pathways was performed using The Database for
Annotation, Visualization and Integrated Discovery (DAVID,
version 6.7, http://www.david.abcc.ncifcrf.org). For this analysis,
probe sets with a corrected p-value ,0.001 and a .2.0-fold
change were used as input. The EASE score, a modified Fisher’s
exact p-value test, was used to adjust for multiple testing.
Development of a Gene Signature
A supervised learning strategy was applied to the microarray
data of the CD452/CD312 SP and MP populations (i.e. the
purified SP or pSP, and the pMP). A list of 200 genes of interest
was composed based on a thorough literature study using the
following terms: ‘pancreatic cancer’, ‘cancer stem cell’, ‘side
population’, ‘canonical pathways’, ‘stemness genes’, ‘epithelial
mesenchymal transition (EMT)’, ‘multidrug resistance’, ‘onco-
genes’ and ‘polycomb genes’. The preprocessed data were limited
to 512 probe sets (195 genes) that had gene symbols in the list of
200 genes of interest. In total, 29 different classification
approaches were used, representing various combinations of 5
classification models, 3 modes of feature selection and 3 ranking
methods [16]. Evaluation of these approaches was done using the
Prognostic Value of SP in Pancreatic Cancer
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leave-one-out-cross-validation (LOOCV) to create a receiver
operating characteristic (ROC) curve [17]. The univariate feature
selection methods turned out to have no added value since the
optimal approach with highest area under the ROC curve (AUC)
and lowest balanced error rate (BER) consisted of a support vector
machine without prior feature ranking or selection (data not
shown). To further reduce the gene signature, we used the PINTA
strategy for gene candidate prioritizing [18]. By looking at
differential expression of the neighbourhood of a gene in a
genome-wide protein-protein interaction network, the PINTA
strategy effectively performs multivariate feature selection through
the incorporation of prior knowledge of molecular biology. A
group of 32 genes was assigned as being significant, and the probe
sets with the highest expression level were chosen. Finally, the
PINTA signature was further narrowed to those 10 genes with the
largest fold change (up or down).
The predictive value of the 32-gene and the reduced 10-gene
signature was validated with LOOCV on different SP versus MP
data sets.
nCounter Analysis
Between 2006 and 2010, tissue samples were collected, after
informed consent, from patients who underwent pancreatic
resection for PDAC. Samples were stored at 280uC in RNALater
(Qiagen). From the primary tumor of 143 patients and from
surrounding non-tumoral pancreatic (control) tissue of 14 patients,
total RNA was extracted using the RNeasy Mini kit (Qiagen)
according the manufacturer’s instructions. Only samples with an
RNA integrity number (RIN) of .7.0 were used for further
analysis, i.e. 78 PDAC samples (male/female ratio: 41/37; age:
32–80 yr with median of 64 yr) and 6 control tissues (male/female
ratio: 4/2; age: 51–66 yr with median of 63 yr). Tumor
characteristics and prognostic features (with a follow-up until July
2011) of the 78 patients are provided (see Table S1). Using the
nCounter system (Nanostring Technologies, Seattle, WA), expres-
sion levels of the above-defined signature genes were quantified in
pancreatic tumor versus surrounding tissue (VIB Nucleomics Core)
[19].
ABCB1 Immunohistochemistry in PDAC Resection
Specimens
To analyze the expression of ABCB1 protein by immunohis-
tochemistry, 5-mm sections were prepared from formalin-fixed
paraffin-embedded PDAC specimens of the 11 patients whose pSP
and pMP RNA were used for microarray analysis. After
deparaffinization and rehydration of the slides, target retrieval
was done with EnVision FLEX Target Retrieval Solution (Dako,
Glostrup, Denmark) during 20 min. Endogenous peroxidase
activity was blocked using EnVision Peroxidase-Blocking Reagent
(Dako) for 5 min. Sections were incubated with primary antibody
(anti-human ABCB1 from Monosan, Uden, The Netherlands) at
the recommended dilution (1/20) for 30 min at room tempera-
ture. Subsequently, the slides were processed using the EnVision
Dual Link (Dako). The complex was visualized with DAB (3,39-
diaminobenzidine; Dako), followed by a hematoxylin (Dako)
counterstaining. Pictures were taken with a Leica DC 300 camera
on a Leica DMLB microscope.
Statistical Analysis
SAS Statistical Software (version 9.1; SAS Institute, Cary, NC)
was used for all statistical analyses. A p-value ,0.05 was
considered statistically significant. Disease-free survival (DFS)
and overall survival (OS) were calculated using the Kaplan-Meier
method (Table S1). To test prognostic value of genes, univariate
analysis for DFS and OS was performed using Cox regression with
and without restricted cubic splines (RCS), followed by multivar-
iate analysis for OS using Cox regression. A selected model was
used for analysis independent of variables already correlated with
survival (ECLNI, gender, pM and pT; see Table S1).
Results
Human Pancreatic Cancer Contains a Side Population
Human PDAC resection specimens were analyzed for the
presence of a side population (SP). In all samples examined
(n= 52), a SP was identified representing between 0.2 and 21.5%
(median: 1.8%) of the total PDAC cells (Fig. 1A).
SP and ‘main population’ (MP) cells (see Fig. 1A for gating) were
sorted by FACS and subjected to whole-genome expression
profiling (n = 10 PDAC). Ingenuity Pathway Analysis (IPA)
revealed in the SP genes and pathways related to immunological
processes, such as ‘T-helper cell differentiation’, ‘Communication
between innate and adaptive immune cells’ and ‘Dendritic cell
maturation’ (data not shown). Immune-type cells, as well as
endothelial cells, are known to co-segregate at varying extents in
the SP of tissues and tumors. Therefore, we analyzed the human
PDAC SP by flow cytometry for the expression of the immune/
hematopoietic marker CD45 and the endothelial marker CD31.
About 60% of the SP cells are CD45+ (median: 61.4%, range:
19.5–75.4%; n= 18) while only a small number of SP cells are
CD31+ (median: 0.7%, range: 0.2–2.1%; n= 15) (Fig. 1B). CD45+
and CD31+ cells were also observed in the MP at comparable
levels (median 63.7% and 1.6%; and range: 41.1–75.4% and 0.1–
6.7%, respectively). For subsequent analyses, the SP and MP were
depleted from the CD45+ and CD31+ cells.
The Purified PDAC SP Shows Expression of CSC-
associated Genes
We sorted the CD452/CD312 SP and CD452/CD312 MP
cells (further referred to as purified SP or pSP, and purified MP or
pMP, respectively) from 11 PDAC samples and again performed
whole-genome expression profiling. Principal Component Analysis
(PCA) shows that the pSPs cluster and segregate from the pMPs
(Fig. 1C).
Of the 1861 probe sets that are differentially expressed ($2-fold,
p,0.001), 993 are upregulated in the pSP and 868 are
downregulated (see GEO, accession number GSE42404). The
multidrug transporter ABCB1 (MDR1, P-glycoprotein) is highly
upregulated in the pSP versus the pMP (fold: 5.3, p,0.001), and
is potentially underlying the SP phenotype. Immunohistochemical
analysis confirmed ABCB1 expression in PDAC tumor cells,
mainly located at the apical surface of the cells (n = 11 PDAC
samples; Fig. 1D). ABCG2, another transporter that can mediate
SP efflux, is not differentially expressed (p.0.5), but the
microarray signal was generally low and not above background
in half of the samples. Interestingly, previously described
pancreatic CSC markers (including CD44, CD133 and CXCR4)
are significantly overexpressed in the pSP (Table S2). In addition,
other (cancer) ‘stemness’ genes (like LGR4, SOX9, KLF5 and MET)
are also upregulated in the pSP.
Of all differentially expressed probe sets, 1690 could be mapped
to genes in the Ingenuity Knowledge Base and were subjected to
IPA (Table S3). The networks most upregulated in the pSP are
‘Amino acid metabolism’ (which includes HNF4A or ‘Hepatocyte
nuclear factor 4 alpha’, fold: 2.7, p,0.001), ‘Cell-to-cell signaling’
(which includes TJP2 or ‘Tight junction protein 29, fold: 2.4,
p,0.001) and ‘Cellular growth and proliferation’ (which includes
Prognostic Value of SP in Pancreatic Cancer
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Figure 1. Identification and molecular characterization of the human PDAC SP. A) Dot plot of dual-wavelength FACS analysis of fresh
human PDAC cells after incubation with Hoechst33342 depicting a tail of ‘Hoechst-low’ cells (SP), relative to a larger bulk of ‘Hoechst-bright’ cells, the
main population (MP) (left panel). A representative example is shown and the SP proportion indicated. PIpos (dead) cells were excluded from analysis
for Hoechst33342, CD45 and CD31 labelling. The boxplot (inset) summarizes the SP proportions of the 52 PDAC samples analyzed. Verapamil blocks
Hoechst efflux, thereby reducing the SP size and confirming the SP phenotype (right panel). B) FACS dot plot of the PDAC SP, immunostained for
Prognostic Value of SP in Pancreatic Cancer
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EPHA2 or ‘Ephrin receptor A2’, fold: 2.1, p,0.001; and EPHA4,
fold: 2.6, p,0.001).
Biological functions enriched in the pSP versus the pMP
encompass ‘Cellular movement’, ‘Cell-to-cell signaling and inter-
action’, ‘Cellular growth and proliferation’, ‘Embryonic develop-
ment’, ‘Tumor morphology’ and ‘Cancer’ (Table S3). To
discriminate between pSP- and pMP-associated biological func-
tions in more detail, DAVID analysis was applied. Clusters related
to ‘Cell-cell junction’ (Enrichment Score or ES: 6.8), ‘Protein
kinase activity’ (ES: 3.4), ‘Development’ (ES: 3.0), ‘Mitogen
activated (MAP) kinase activity’ (ES: 1.8), ‘Integrin signaling’
(ES: 1.6) and ‘Regulation of apoptosis’ (ES: 1.4) are enriched in the
pSP.
Canonical pathways, based on differentially expressed genes,
were also analyzed using IPA. A number of 46 canonical pathways
reached the significant SP enrichment cut-off of p,0.05, including
‘Human embryonic stem cell pluripotency’, ‘Tight junction
signaling’, ‘NF-kB signaling’, ‘Wnt/b-catenin signaling’, ‘Integrin
signaling’ and ‘Ephrin signaling’ (Table S3). Further detailed
analysis using DAVID (KEGG pathways) showed upregulation of
the ‘ErbB signaling pathway’ (including ErbB3, fold: 2.1, p,0.001)
in the pSP.
Gene Signatures that Discriminate the PDAC pSP from
the pMP
Using a supervised learning strategy applied to the whole-
genome expression data from the 11 CD452/CD312 pSP and
pMP pairs as analyzed above, we developed a set of 512 probe sets
(195 genes) as potential ‘pSP gene signature’. The accuracy to
discriminate between pSP and pMP using this signature was 95%
in the training cohort, as evaluated with LOOCV (see Materials
and Methods).
Using PINTA (see Materials and Methods), this large pSP gene
signature was reduced to 32 genes, of which 19 are upregulated
and 13 downregulated (Table S4). Validation of this reduced pSP
gene signature in the original dataset (n = 11 PDAC samples)
demonstrated a 91% classification accuracy of pSP and pMP,
comparable to the prediction using the 195-gene signature. Within
the 32-gene signature, genes upregulated in the pSP include
previously proposed pancreatic CSC markers (CXCR4, CD133) or
play a role in multidrug resistance (ABCB1) and in pathways
important in tumorigenesis and tumor progression (see Table S4).
Finally, we further narrowed the gene signature to those 10
genes with largest fold up- or downregulation (Table S4, in bold).
The accuracy of this condensed gene signature to distinguish pSP
from pMP (90%) is comparable to the discriminatory power of the
32-gene set.
As an ultimate test of the discriminating value of the 32- and 10-
gene signatures, we applied both sets to an additional, independent
series of 10 SP/MP pairs using LOOCV. Both gene signatures
presented a discriminating accuracy between SP and MP of 85%.
Prognostic Value of ABCB1 and CXCR4
To investigate whether genes of the pSP (32- and 10-)gene
signatures have prognostic value, expression levels were first
determined in an independent series of patients (n = 78; Table S1)
in tumor versus surrounding tissue using nCounter analysis (see
Materials and Methods) and then subjected to univariate analysis
for potential correlation with prognosis/survival. First, signature
genes overexpressed in the pSP are related to prognosis whereas
no correlation was found with signature genes downregulated in
the pSP (data not shown). Moreover, upregulation of ABCB1 and
CXCR4 is significantly correlated with worse prognosis, i.e. with
lowest OS and DFS (Table S5). Multivariate analysis was then
performed on the genes with p,0.1 in univariate analysis (ABCB1,
ADAM10, CDH1, CXCR4, ESRP1, MMP1, RAB25, ST14),
designating ABCB1 as an independent predictor of poor OS
(Table S5).
Discussion
In the present study, we identified a SP in human pancreatic
cancer. To our knowledge, this is the first report describing the
presence of a SP in PDAC analyzed from patients. Like in other
tissues and tumors, the PDAC SP contains a fraction of CD31+
endothelial cells and CD45+ immune cells [20]. In the current
study, we focused on the non-endothelial, non-immune SP (pSP)
and scrutinized its gene expression profile. The pSP mainly
represents tumoral epithelial cells given the high expression of
CDH1, EPCAM, TJP1 and TJP2 [21]. In this PDAC pSP we
found upregulation of the multidrug transporter ABCB1, which
may be responsible for chemoresistance of these cells. Immuno-
staining confirmed the presence of ABCB1 in PDAC, mainly
located at the apical surface of the tumor cells where active drug
transport may occur. Upregulation of apoptosis-regulating factors
(Bcl2L11, fold: 2.9, p,0.001; EPHA2, see Results) in the PDAC
pSP may further support its chemoresistant character. We have
recently shown that the SP is highly resistant to gemcitabine in a
mouse model in which PDAC was grown as xenografts [12].
Resistance of the SP to gemcitabine has also been reported in
pancreatic cancer cell lines in vitro [8,9,11]. Taken together, the SP
appears to represent a chemoresistant subpopulation of the
pancreatic tumor, and may thus be one of the culprits for
treatment failure and cancer recurrence.
In several types of cancer, the SP is enriched for candidate CSC
[7,22]. We found that markers recently identified in putative CSC
populations of human pancreatic cancer, are upregulated in the
PDAC pSP. In addition, we detected some other ‘cancer stemness’
markers (e.g. LGR4, SOX9, KLF5, MET) as well as pancreatic
embryogenesis-related factors which may be re-initiated in CSC
(e.g. HNF4A) [5,6,23–26]. Moreover, in silico functional analysis of
the expression data highlights the occurrence of pathways of
embryonic development and embryonic stem cell pluripotency in
the PDAC SP, further supporting its ‘stemness’. Also in pancreatic
cancer cell lines, the SP appeared enriched in CSC [9–11].
Nevertheless, it is clear that more evidence is needed to
conclusively demonstrate the CSC phenotype of the pSP,
including tumorigenic activity in vitro (sphere formation) and in vivo
(tumor growth in immunodeficient mice).
The PDAC pSP may represent an interesting therapeutic target
given its chemoresistance- and CSC-associated character. The
pSP cells express high levels of CXCR4, which upon activation,
may stimulate the cells to move or to undergo ‘epithelial-
mesenchymal transition’ (EMT), a process driving cancer
progression and malignancy. In pancreatic cancer cell lines, the
SP can indeed be activated towards EMT when treated with
CD45 and CD31. A representative example is shown. Numbers indicate the proportions of CD45+, CD31+ and CD452/CD312 cells within the SP. C)
Principal Component Analysis (PCA) of whole genome expression profiles obtained from CD452/CD312 SP (pSP, red) and CD452/CD312 MP (pMP,
blue) (n = 11). D) Immunohistochemical staining of ABCB1 in PDAC resection samples (n = 11). A representative example (4% SP in FACS analysis) is
shown. Original magnification: x200 (left) and x400 (right).
doi:10.1371/journal.pone.0073968.g001
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TGFb [21]. In the PDAC pSP, we observed upregulation of
SMAD3, known to mediate TGFb signaling. Further interestingly,
CXCL12, the ligand of CXCR4, is highly expressed in the
surrounding pancreatic tissue of the PDAC tumor (data not
shown) and may lure cells out of the tumor for invasion or further
dissemination. In analogy, CXCR4 expression has been found to
characterize a subpopulation of the CD133+ pancreatic CSC that
seem to be reponsible for the metastasis of the tumor [6,27].
Upregulation of EPHA2 and EPHA4 in the pSP is in line with an
important role of the Ephrin signaling pathway in PDAC
pathogenesis. Expression of EPHA2 in PDAC has been associated
with increased invasive and metastatic ability and poor survival
[28]. Knockdown of EPHA4 expression decreases PDAC cell
viability [29]. In addition, we found that the ErbB signaling
pathway is upregulated in the pSP (KEGG analysis), including the
higher expression of ErbB3. The ErbB3 receptor plays a crucial
role in pancreatic development as well as in pancreatic tumori-
genesis. Overexpression of ErbB3 correlates with advanced PDAC
stage and decreased overall survival, and recently, its role as potent
mediator of PI3K signaling has been highlighted [30,31].
Moreover, activation of ErbB3 may be essential in the resistance
to single-agent EGFR inhibition. Specifically inhibiting ErbB3
activity (e.g. with MM-121) appears promising in vitro, and thus
may also have clinical potential [31]. Both the Ephrin and ErbB
signaling pathways may present potential therapeutic targets in
PDAC. It should be noted that our study did not examine the
prognostic value of EPHA2 and ErbB3 since these genes were not
included in the pSP signatures evaluated against survival.
The developed pSP gene signatures trustfully discriminate the
pSP from the pMP. Some of the upregulated genes are related to
CSC/’cancer stemness’ such as CXCR4, CD133, EPCAM and
SOX9 [5,6,24], while others are associated with apoptosis (FASLG,
TJP2, DUSP4), the MAPK pathway (MAP2K4, DUSP4), and
chemoresistance (MMP1, an ETS1 target gene) [32,33]. In
addition, the signature contains genes related to increased motility
and invasion (ADAM10, RAB25, DUSP4, CXCR4). Also some of
these genes may represent promising targets.
Finally, we evaluated the prognostic relevance of genes included
in the pSP signatures. CXCR4 and ABCB1 are negatively related to
survival after curative resection, which is also found in other
reports [34,35]. CXCR4 has previously been connected with
metastatic PDAC CSC and inhibiting CXCR4 with AMD3100
in vivo resulted in reduced metastasis [6,27]. Our data support
CXCR4 as an interesting pSP2/CSC-associated target, which
additionally presents prognostic relevance. ABCB1 has been
studied as a potential therapeutic target in other cancers. In a
model for ovarian cancer, drug resistance was reverted after
downregulation of ABCB1 by shRNA [36]. We have shown that
ABCB1 may also play a role in PDAC, as it is related to therapy
resistance and affects patient outcome [37,38]. However, treat-
ment-related toxicity needs substantial consideration, as ABCB1 is
also present on a large variety of normal cells participating in
physiological processes. Therefore, further study is needed to
confirm the clinical impact of the SP. For instance, potentially
important genes upregulated in the SP may be knocked down by
siRNA/shRNA, to evaluate the impact on tumorigenesis in
immunodeficient mice.
In conclusion, we identified a SP in human PDAC. Gene
expression profiling revealed chemoresistance- and CSC-associat-
ed characteristics and yielded (new) candidate therapeutic targets
with potential prognostic value.
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